SCHEMBL4525402

SCHEMBL4525402

Cc1ccc(CNCC2CC2)cc1C#Cc1ccc(/C=C/C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.54
HDAC3 O15379 4/20 0.46
HDAC1 Q13547 4/20 0.46
HDAC8 Q9BY41 4/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC4 P56524 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
AKR1C3 P42330 3/20 0.41
AKR1C2 P52895 2/20 0.41
HDAC2 Q92769 3/20 0.37
CXCR4 P61073 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CHRM2 P08172 1/20 0.36
S1PR1 P21453 1/20 0.36
FPR1 P21462 1/20 0.36
FPR3 P25089 1/20 0.36
GPR183 P32249 1/20 0.36
APLNR P35414 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
GPR65 Q8IYL9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522411 0.88 HDAC3 (0.43) FFAR1HDAC3HDAC1HDAC8HDAC6
SCHEMBL4523871 0.83 FFAR1 (0.54) FFAR1HDAC3HDAC1HDAC8HDAC6
SCHEMBL4525407 0.80 FFAR1 (0.54) FFAR1HDAC3HDAC6AKR1C3AKR1C2
SCHEMBL4525397 0.80 FFAR1 (0.54) FFAR1HDAC3HDAC6AKR1C3AKR1C2
SCHEMBL4519671 0.74 PTGES (0.45) FFAR1HDAC3HDAC1HDAC8HDAC6
SCHEMBL4523192 0.72 FFAR1 (0.64) FFAR1ATM
SCHEMBL4523194 0.72 FFAR1 (0.64) FFAR1ATM
SCHEMBL5706323 0.72 PRMT5 (0.39) HDAC1HDAC6CXCR4MEN1KMT2A
SCHEMBL4509831 0.72 PRMT5 (0.39) HDAC6CXCR4MEN1KMT2A
SCHEMBL13606706 0.71 FFAR1 (0.41) FFAR1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638648-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN INC. (US) 2009-12-29 US disclosed
US-7468391-B2 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2008-12-23 US disclosed
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2008-01-03 US disclosed
US-7226951-B2 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. (US) 2007-06-05 US disclosed
US-20050187298-A1 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B ALLERGAN, INC. (US) 2005-08-25 US disclosed
US-20050176689-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same ALLERGAN, INC. 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176689-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same CYP1A2, CYP2A7, CYP3A7 FFAR1 1474/4885HDAC3 2122/4885HDAC1 1430/4885
US-20050187298-A1 Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B CYP26B1, CYP2A6, CYP21A2 FFAR1 864/4885HDAC3 3250/4885HDAC1 3275/4885
US-20080004455-A1 Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same CYP1A2, CYP2A7, CYP3A7 FFAR1 1474/4885HDAC3 2122/4885HDAC1 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.